Halladay Benjamin 4

What Happened
Benjamin Halladay, Chief Financial Officer of Esperion Therapeutics (ESPR), received equity awards on 2026-03-13 totaling 468,700 shares: 247,430 shares granted at $0.00 and 221,270 shares reported as a derivative award at $0.00 (total acquisition value reported $0). These awards are part of his compensation and are not open-market purchases or sales.

Key Details

• Transaction date: 2026-03-13; Form 4 filed 2026-03-16 (filed within the standard two business-day reporting window).
• Grants: 247,430 shares @ $0.00 (award); 221,270 shares @ $0.00 (derivative award). Combined = 468,700 shares.
• Vesting: The award(s) vest over four years in equal quarterly installments; first vesting date is June 15, 2026 (Footnote F1).
• Ownership note: Footnote F2 states reported holdings include 5,071 shares recently purchased through Esperion’s Employee Stock Purchase Plan.
• Transaction type: A = Award/Grant (not a purchase or sale), so this reflects compensation rather than an immediate market view.

Context
Equity awards to executives are common as compensation and typically vest over time; they do not by themselves signal an immediate buying or selling decision. The derivative line likely refers to restricted stock units or similar equity-based awards that settle into shares upon vesting.